Enovis Corp
Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions in the United States and internationally. It operates through two segments: Prevention and Recovery, and Reconstructive segments. The company's Prevention and Recovery segment offers orthopedic solutions and recovery sciences including rigid and soft orthopedic bracing, hot and cold… Read more
Enovis Corp (ENOV) - Net Assets
Latest net assets as of September 2025: $2.02 Billion USD
Based on the latest financial reports, Enovis Corp (ENOV) has net assets worth $2.02 Billion USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($4.43 Billion) and total liabilities ($2.41 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $2.02 Billion |
| % of Total Assets | 45.65% |
| Annual Growth Rate | 17.72% |
| 5-Year Change | -28.53% |
| 10-Year Change | -21.26% |
| Growth Volatility | 287.56 |
Enovis Corp - Net Assets Trend (2004–2024)
This chart illustrates how Enovis Corp's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Enovis Corp (2004–2024)
The table below shows the annual net assets of Enovis Corp from 2004 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $2.56 Billion | -25.03% |
| 2023-12-31 | $3.42 Billion | -0.84% |
| 2022-12-31 | $3.45 Billion | -25.99% |
| 2021-12-31 | $4.66 Billion | +29.92% |
| 2020-12-31 | $3.59 Billion | +2.82% |
| 2019-12-31 | $3.49 Billion | +0.36% |
| 2018-12-31 | $3.48 Billion | -6.72% |
| 2017-12-31 | $3.73 Billion | +20.49% |
| 2016-12-31 | $3.09 Billion | -5.01% |
| 2015-12-31 | $3.26 Billion | -2.86% |
| 2014-12-31 | $3.35 Billion | +22.30% |
| 2013-12-31 | $2.74 Billion | +27.12% |
| 2012-12-31 | $2.16 Billion | +1039.23% |
| 2011-12-31 | $189.28 Million | -12.52% |
| 2010-12-31 | $216.37 Million | +8.82% |
| 2009-12-31 | $198.83 Million | +19.11% |
| 2008-12-31 | $166.93 Million | +214.66% |
| 2007-12-31 | $53.05 Million | +799.32% |
| 2006-12-31 | $5.90 Million | +177.83% |
| 2005-12-31 | $-7.58 Million | -107.73% |
| 2004-12-31 | $98.09 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Enovis Corp's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 28302300000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $56.00K | 0.00% |
| Other Comprehensive Income | $-127.89 Million | -4.99% |
| Other Components | $2.97 Billion | 116.04% |
| Total Equity | $2.56 Billion | 100.00% |
Enovis Corp Competitors by Market Cap
The table below lists competitors of Enovis Corp ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Nishi-Nippon Railroad Co. Ltd
F:NNR
|
$1.26 Billion |
|
Citic Offshore Helicopter Co Ltd
SHE:000099
|
$1.26 Billion |
|
Hacksaw
ST:HACK
|
$1.26 Billion |
|
KOEI TECMO HLDGS CO. LTD.
F:85T
|
$1.26 Billion |
|
Guangzhou Haozhi Industrial Co Ltd
SHE:300503
|
$1.26 Billion |
|
DEME Group NV
BR:DEME
|
$1.26 Billion |
|
FAIRFAX INDIA HLDGS
F:F5X
|
$1.26 Billion |
|
SKC Co. Ltd
KO:011790
|
$1.26 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Enovis Corp's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 3,418,392,000 to 2,562,262,000, a change of -856,130,000 (-25.0%).
- Net loss of 825,494,000 reduced equity.
- Share repurchases of 4,772,000 reduced equity.
- New share issuances of 1,874,000 increased equity.
- Other comprehensive income decreased equity by 103,011,000.
- Other factors increased equity by 75,273,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-825.49 Million | -32.22% |
| Share Repurchases | $4.77 Million | -0.19% |
| Share Issuances | $1.87 Million | +0.07% |
| Other Comprehensive Income | $-103.01 Million | -4.02% |
| Other Changes | $75.27 Million | +2.94% |
| Total Change | $- | -25.04% |
Book Value vs Market Value Analysis
This analysis compares Enovis Corp's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.51x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 1.74x to 0.51x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2004-12-31 | $13.45 | $23.46 | x |
| 2005-12-31 | $-1.04 | $23.46 | x |
| 2006-12-31 | $0.81 | $23.46 | x |
| 2007-12-31 | $7.27 | $23.46 | x |
| 2008-12-31 | $14.90 | $23.46 | x |
| 2009-12-31 | $13.73 | $23.46 | x |
| 2010-12-31 | $14.81 | $23.46 | x |
| 2011-12-31 | $12.83 | $23.46 | x |
| 2012-12-31 | $63.32 | $23.46 | x |
| 2013-12-31 | $74.35 | $23.46 | x |
| 2014-12-31 | $76.11 | $23.46 | x |
| 2015-12-31 | $73.76 | $23.46 | x |
| 2016-12-31 | $70.54 | $23.46 | x |
| 2017-12-31 | $84.69 | $23.46 | x |
| 2018-12-31 | $81.16 | $23.46 | x |
| 2019-12-31 | $75.54 | $23.46 | x |
| 2020-12-31 | $76.53 | $23.46 | x |
| 2021-12-31 | $90.29 | $23.46 | x |
| 2022-12-31 | $63.78 | $23.46 | x |
| 2023-12-31 | $62.73 | $23.46 | x |
| 2024-12-31 | $46.35 | $23.46 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Enovis Corp utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -32.22%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -39.17%
- • Asset Turnover: 0.45x
- • Equity Multiplier: 1.84x
- Recent ROE (-32.22%) is below the historical average (9.11%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2004 | 58.42% | 18.51% | 0.44x | 7.22x | $47.50 Million |
| 2005 | 0.00% | 3.54% | 0.49x | 0.00x | $13.00 Million |
| 2006 | 1.59% | 0.02% | 0.49x | 135.15x | $-495.90K |
| 2007 | 122.30% | 12.81% | 0.56x | 16.90x | $59.58 Million |
| 2008 | -0.34% | -0.09% | 0.66x | 5.47x | $-17.26 Million |
| 2009 | 10.92% | 4.14% | 0.52x | 5.05x | $1.84 Million |
| 2010 | 7.49% | 2.99% | 0.53x | 4.72x | $-5.42 Million |
| 2011 | 2.41% | 0.66% | 0.64x | 5.75x | $-14.37 Million |
| 2012 | -3.37% | -1.65% | 0.64x | 3.21x | $-255.64 Million |
| 2013 | 7.11% | 4.25% | 0.64x | 2.62x | $-72.76 Million |
| 2014 | 12.46% | 8.48% | 0.64x | 2.30x | $77.42 Million |
| 2015 | 5.46% | 4.23% | 0.59x | 2.19x | $-139.26 Million |
| 2016 | 4.42% | 3.51% | 0.57x | 2.20x | $-161.58 Million |
| 2017 | 4.32% | 4.58% | 0.49x | 1.92x | $-198.95 Million |
| 2018 | 4.29% | 6.39% | 0.33x | 2.02x | $-186.78 Million |
| 2019 | -15.33% | -15.86% | 0.45x | 2.15x | $-871.79 Million |
| 2020 | 1.20% | 1.39% | 0.42x | 2.07x | $-311.71 Million |
| 2021 | 1.55% | 5.02% | 0.17x | 1.84x | $-390.08 Million |
| 2022 | -0.39% | -0.85% | 0.37x | 1.24x | $-358.10 Million |
| 2023 | -0.97% | -1.95% | 0.38x | 1.32x | $-375.10 Million |
| 2024 | -32.22% | -39.17% | 0.45x | 1.84x | $-1.08 Billion |
Industry Comparison
This section compares Enovis Corp's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $694,749,556
- Average return on equity (ROE) among peers: -25.46%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Enovis Corp (ENOV) | $2.02 Billion | 58.42% | 1.19x | $1.26 Billion |
| Advanced Biomedical Technologies Inc (ABMT) | $-4.46 Million | 0.00% | 0.00x | $14.18K |
| Abbott Laboratories (ABT) | $4.82 Billion | 39.04% | 1.31x | $191.37 Billion |
| Acarix AB (publ) (ACIXF) | $1.93 Million | -127.02% | 0.21x | $26.42 Million |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-72.62 Million | 0.00% | 0.00x | $4.05 Million |
| Adm Tronics Unltd (ADMT) | $-12.69K | 0.00% | 0.00x | $3.17 Million |
| Aethlon Medical Inc (AEMD) | $-3.07 Million | 0.00% | 0.00x | $2.79 Million |
| Acutus Medical Inc (AFIB) | $126.58 Million | -80.56% | 0.52x | $732.88K |
| Adapthealth Corp (AHCO) | $2.07 Billion | 7.56% | 1.54x | $914.25 Million |
| Allied Healthcare Products Inc. (AHPIQ) | $8.88 Million | -33.95% | 1.22x | $726.24 |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $3.39 Million | -59.65% | 0.38x | $9.18 Million |